News
ZIOP
--
0.00%
--
Cancer Gene Therapy Market 2021 Global Industry Trends, Revenue Analysis, Statistics, Competition Strategies, Size, Share, Growth, Key Players, Regional Analysis by Forecast to 2025
Jan 21, 2021 (The Expresswire) -- Global "Cancer Gene Therapy Market" report covers the present state of Market Share, CAGR, Revenue, Gross Market and the...
The Express Wire · 4d ago
8-K: ZIOPHARM ONCOLOGY INC
(EDGAR Online via COMTEX) -- ZIOPHARM ONCOLOGY INC false 0001107421 0001107421 2021-01-14 2021-01-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/14 16:44
ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022
At J.P. Morgan Healthcare Conference, Ziopharm Oncology ([[ZIOP]] +12.3%) said that cash/equivalents of $135.5M as of 30 September would be sufficient to fund planned operations and execute strategy into mid-2022.Upcoming
Seekingalpha · 01/14 15:33
Ziopharm gains after electing venture capital partner as Chairman
Ziopharm Oncology ([[ZIOP]] +12.3%)  has elected James Huang as Chairman of the Board of Directors, effective immediately. Mr. Huang has served on the Board since July 2020 and is currently a Managing Partner at Kleiner
Seekingalpha · 01/14 15:33
*DJ Ziopharm Oncology Names Heidi Hagen as Lead Independent Director
Dow Jones · 01/14 13:01
*DJ Ziopharm Oncology Names James Huang as Chairman
Dow Jones · 01/14 13:01
Ziopharm Oncology Announces Election of James Huang as Chairman of the Board of Directors
- Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation -
GlobeNewswire · 01/14 13:00
Ziopharm Oncology Announces Election of James Huang as Chairman of the Board of Directors
– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director –BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasda...
GlobeNewswire · 01/14 13:00
Ziopharm to Participate in Upcoming January Conferences
Ziopharm Oncology, Inc. ("Ziopharm" or "the Company") (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 Conference a...
GlobeNewswire · 12/23/2020 21:01
Ziopharm to Participate in Upcoming January Conferences
BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H....
GlobeNewswire · 12/23/2020 21:01
Companies Like ZIOPHARM Oncology (NASDAQ:ZIOP) Are In A Position To Invest In Growth
Simply Wall St. · 12/23/2020 10:14
The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 20)
Benzinga · 12/22/2020 12:45
The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 20) * Acceleron Pharma Inc (NASDAQ: XLRN) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * Allakos Inc (NASDAQ:...
Benzinga · 12/22/2020 12:45
SPWH, MVIS, CCXI and VERO among after-hours movers
Gainers: [[SPWH]] +36.8%. [[MVIS]] +15.8%. [[QS]] +9.9%. [[SI]] +9.2%. [[ZIOP]] +8.9%.Losers: [[CVGW]] -16.9%. [[CCXI]] -16.3%. [[VERO]] -14.9%. [[CNTG]] -9.4%. [[TUSK]] -7.3%.
Seekingalpha · 12/21/2020 22:50
Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients
The regulatory authority in Taiwan has signed off investigational new drug application from Eden BioCell, a 50-50 joint venture between Ziopharm Oncology (ZIOP) its partner TriArm Therapeutics, for Phase 1 trial to
Seekingalpha · 12/21/2020 21:14
Ziopharm Oncology Announces Clearance of Taiwan's First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas
- Advances Eden BioCell's clinical program to validate Rapid Personalized Manufacturing (RPM) -
GlobeNewswire · 12/21/2020 21:01
Ziopharm Oncology Announces Clearance of Taiwans First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas
– Advances Eden BioCell’s clinical program to validate Rapid Personalized Manufacturing (RPM) – – Clinical trial to study autologous CD19-specific CAR-T using RPM technology designed to reduce cost and simplify production for infusion the day after gene t...
GlobeNewswire · 12/21/2020 21:01
Activist holder wins Ziopharm Oncology board seats
Ziopharm Oncology ([[ZIOP]] +1.6%) reports the election of Jaime Vieser and Holger Weis to its board of directors in a consent solicitation initiated by WaterMill Asset Management.Chairman Scott Tarriff is
Seekingalpha · 12/17/2020 15:49
WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology
WaterMill Asset Management Corp. (together with its affiliates, "WaterMill" or "we"), a sizable and long-term shareholder of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) ("Ziopharm" or the "Company"), today announced that it received the requisite number of writ...
Business Wire · 12/17/2020 14:00
Are Options Traders Betting on a Big Move in Ziopharm (ZIOP) Stock?
Zacks · 12/17/2020 13:56
Webull provides a variety of real-time ZIOP stock news. You can receive the latest news about ZIOPHARM Oncolgy through multiple platforms. This information may help you make smarter investment decisions.
About ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
More